MIR-140 TARGETS LNCRNA DNAJC3-AS1 TO SUPPRESS CELL PROLIFERATION IN ACUTE MYELOID LEUKEMIA AML proliferation and MIR-140 LNCRNA DNAJC3-AS1 target.

Main Article Content

Hong Li
a:1:{s:5:"en_US";s:39:"Shandong Provincial Qianfoshan Hospital";}

Kehong Bi
Saran Feng
Yan Yan Wang
Chuansheng Zhu

Keywords

Abstract

Objectives：MiR-140 and DNAJC3-AS1 have been proven to play critical roles in cancer biology, while their participations in acute myeloid leukemia (AML) are unclear. This study aimed to explore the role of miR-140 and DNAJC3-AS1 in AML.


Methods：Analysis of the expression of DNAJC3-AS1 and miR-140 was done with RT-qPCR. The role of DNAJC3-AS1 and miR-140 in the expression of each other was explored with overexpression assay. The direct interaction between DNAJC3-AS1 and miR-140 was analyzed with RNA pull-down assay. The subcellular location of DNAJC3-AS1 was explored with cellular subcellular fractionation assay. Cell proliferation analysis was done with BrdU assay.


Results：AML patients showed increased expression of DNAJC3-AS1 and decreased expression of miR-140. DNAJC3-AS1 was detected in both nuclear and cytoplasm samples, and a direct interaction between DNAJC3-AS1 and miR-140 was observed.  


Discussion：Reduced expression of DNAJC3-AS1 was observed after miR-140 overexpression in AML cells. DNAJC3-AS1 increased cell proliferation and inhibited the role of miR-140 in suppressing cell proliferation.


Conclusion：In conclusion, miR-140 may target DNAJC3-AS1 to suppress cell proliferation in AML.

Downloads

Download data is not yet available.


Abstract 686
PDF Downloads 350
HTML Downloads 151

Article Sidebar

PDF HTML
Published
Jan 1, 2022
DOI https://doi.org/10.4084/mjhid.2022.005

Article Details

How to Cite

Li, H. (2022) “MIR-140 TARGETS LNCRNA DNAJC3-AS1 TO SUPPRESS CELL PROLIFERATION IN ACUTE MYELOID LEUKEMIA: AML proliferation and MIR-140 LNCRNA DNAJC3-AS1 target”., Mediterranean Journal of Hematology and Infectious Diseases, 14(1), p. e2022005. doi: 10.4084/mjhid.2022.005.
Issue
Vol. 14 No. 1 (2022): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Section
Original Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.